SCHEMBL2093371

SCHEMBL2093371

COC(=O)N(c1ccccc1)c1c(F)cc(F)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
ATM Q13315 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NPSR1 Q6W5P4 3/20 0.40
ALDH1A1 P00352 3/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PTGIR P43119 2/20 0.38
CHRM4 P08173 2/20 0.38
CHRM3 P20309 2/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
TACR3 P29371 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2093369 0.84 ATM (0.41) MEN1KMT2ATSHRL3MBTL1ATM
SCHEMBL2090244 0.82 NPSR1 (0.47) MEN1KMT2ATSHRL3MBTL1ATM
SCHEMBL6000722 0.81 PTGIR (0.44) KMT2AL3MBTL1ATMTDP1NPSR1
SCHEMBL2090242 0.80 NPSR1 (0.45) MEN1KMT2ATSHRL3MBTL1ATM
SCHEMBL2092944 0.79 PTGIR (0.52) L3MBTL1ATMTDP1PTGIRTACR3
SCHEMBL3276086 0.79 L3MBTL1 (0.61) MEN1KMT2ATSHRL3MBTL1ATM
SCHEMBL2098123 0.73 ESR1 (0.43) MEN1KMT2ATSHRL3MBTL1ATM
SCHEMBL28111104 0.72 L3MBTL1 (0.47) MEN1KMT2ATSHRL3MBTL1ATM
SCHEMBL27451520 0.72 MEN1 (0.47) MEN1KMT2ATSHRL3MBTL1ATM
SCHEMBL7933016 0.72 EGFR (0.37) MEN1KMT2ATSHRL3MBTL1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 MEN1 4525/4885KMT2A 3324/4885TSHR 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.